Chronic fatigue syndrome differs from fibromyalgia. No evidence for elevated substance P levels in cerebrospinal fluid of patients with chronic fatigue syndrome

Pain

Volumn 78, Issue 2, 1998, Pages 153-155

  Evengard, B ^a   Nilsson, C G ^b   Lindh, G ^a   Lindquist, L ^a   Eneroth, P ^b   Fredrikson, S ^a   Terenius, L ^a   Henriksson, K G ^c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Karolinska I   (Sweden)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Chronic fatigue syndrome; Fibromyalgia; Substance P

Indexed keywords

SUBSTANCE P;

ADULT; ARTICLE; CEREBROSPINAL FLUID LEVEL; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; DIFFERENTIAL DIAGNOSIS; FEMALE; FIBROMYALGIA; HUMAN; MALE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; FATIGUE SYNDROME, CHRONIC; FEMALE; FIBROMYALGIA; HUMANS; MALE; REFERENCE VALUES; SUBSTANCE P;

EID: 0031772214     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3959(98)00134-1     Document Type: Article

References (16)

1. Buchwald D., Umali P., Umali J., Kith P., Pearlman T., Komaroff A.L. Chronic fatigue and the chronic fatigue syndrome: prevalence in a Pacific Northwest health care system. Ann. Intern. Med. 123:1995;81-88.
2. Eneström, S., Bengtsson. A. and Frödin, T., Dermal IgG deposits and increase of mast cells in patients with fibromyalgia-relevant findings of epiphenomena?, Scand. J. Rheumatol., (1998) in press).
3. Foreman, J.C. and Jordan, C.C., Neurogenic inflammation, TIPS, March (1984) 116-119.
4. Fukuda, K., Straus, S.E., Hickie, I., Sharpe, M., Dobbins, J.D., Komaroff, A. and the International Chronic Fatigue Syndrome Group, The chronic fatigue syndrome: a comprehensive approach to its definition and study, Ann. Intern. Med., 12 (1994) 953-959.
5. Henriksson K.G., Bäckman E., Henriksson C., de Laval J.H. Chronic regional muscular pain in women with precise manipulation work. A study of pain characteristics, muscle function, and impact on daily activities. Scand. J. Rheumatol. 25:1996;213-223.
6. Lindh, C., Liu, Z., Lyrenäs, S., Ordeberg, G. and Nyberg, F., Elevated cerebrospinal fluid substance P-like immunoreactivity in patients with painful osteoarthritis, but not in patients with rhizopatic pain from a herniated lumbar disc, Scand. J. Rheumatol., (1997) 468-472.
7. Littlejohn G., Weinstein C., Helme R.D. Increased neurogenic inflammation in fibrositis syndrome. J. Rheumatol. 14(5):1987;1022-1195.
8. Moldofsky H. Fibromyalgia, sleep disorder and chronic fatigue syndrome. Ciba Found. Symp. 173:1993;262-279.
9. Pillemer S.R., Bradley L.A., Crofford L.J., Moldofsky H., Chrousos G.P. The neuroscience and endocrinology of fibromyalgia. Arth. Rheum. 40(11):1997;1928-1939.
10. Reynolds W.J., Chiu B., Inman R.D. Plasma substance P levels in fibrositis. J. Rheumatol. 15:1988;1802-1807.
11. Russell I.J., Orr M.D., Littman B., Vipraio G.A., Alboukrek D., Michalek J.E., Lopez Y., MacKillip F. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum. 37:1994;1593-1601.
12. Russell I.J. Neurochemical pathogenesis of fibromyalgia syndrome. J. Musculoskel. Pain. 4(1-2):1996;61-92.
13. Vaeroy H., Nyberg F., Franzen H., Terenius L. Characterization of a substance P-GLY 12 amidating enzyme in human cerebrospinal fluid. Biochem. Biophys. Res. Commun. 148:1987;24-30.
14. Vaeroy H., Helle R., Forre O., Kass E., Terenius L. Elevated CSF levels of substance P and high incidence of Raynaud's phenomenon in patients with fibromyalgia: new features for diagnosis. Pain. 32:1988;21-26.
15. Wolfe F., Smythe H.A., Yunus M.B., Bennett R.M.et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia, Report of the Multicenter Criteria Committee. Arthritis Rheum. 33(2):1990;160-171.
16. Wolfe F., Ross K., Anderson J., Russel I.J., Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 38(1):1995;19-28.